Rockefeller Capital Management’s Karuna Therapeutics, Inc. Common Stock KRTX Stock Holding History

Rockefeller Capital Management’s Portfolio KRTX Stock Details KRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-19	Closed	-$3K	–	4076
2022 Q4	$3K	Sell	19 -4	-17%	-$858	﹤0.01%	3513
2022 Q3	$5K	Sell	23 -54	-70%	-$10.9K	﹤0.01%	3365
2022 Q2	$9K	Buy	77 +58	+305%	+$6.67K	﹤0.01%	3202
2022 Q1	$2K	Buy	19 +6	+46%	+$676	﹤0.01%	3665
2021 Q4	$1K	Buy	+13	New	+$1.68K	﹤0.01%	3715
2021 Q3	–	Sell	-9	Closed	-$1K	–	3895
2021 Q2	$1K	Buy	+9	New	+$1.05K	﹤0.01%	3398

Other funds holding KRTX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Rockefeller Capital Management's KRTX Position: Q1 2023 in Review

Rockefeller Capital Management sold out of Karuna Therapeutics, Inc. Common Stock (KRTX) in Q1 2023, closing a stake of 19 shares — an estimated $3K sold.

Rockefeller Capital Management first reported a position in KRTX in Q2 2021 and held it in 6 quarters. The position peaked at $9K in Q2 2022. 246 funds tracked by Wall St. Rank hold KRTX as of Q1 2023.

Rockefeller Capital Management reported no remaining Karuna Therapeutics, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
Rockefeller Capital Management sold 19 Karuna Therapeutics, Inc. Common Stock shares in Q1 2023, an estimated $3K.
Rockefeller Capital Management first reported a position in Karuna Therapeutics, Inc. Common Stock in Q2 2021 and held it in 6 quarters.
Rockefeller Capital Management's Karuna Therapeutics, Inc. Common Stock position peaked at $9K in Q2 2022.
246 funds tracked by Wall St. Rank held Karuna Therapeutics, Inc. Common Stock as of Q1 2023.

Based on Rockefeller Capital Management's 13F filing for Q1 2023, filed 16 May 2023.